Mizuho analyst Joseph Catanzaro initiated coverage of Bicara Therapeutics (BCAX) with a Neutral rating and $18 price target The firm believes the company’s ficerafusp alfa is unfavorably positioned in an “increasingly competitive” head and neck cancer landscape. Comparisons with cetuximab indicates little efficacy contribution from ficerafusp’s TGF beta trap, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/8/2025, According to Top Analysts
- Bicara Therapeutics Reports Promising Phase 1b Data
- Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation
- Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating